ICARUS-IBD is a global study lead by researchers from the Translational Gastroenterology Unit at the University of Oxford and the Icahn School of Medicine at the Mount Sinai Hospital.


What is the purpose of the study?

The study focuses on inflammatory bowel disease (IBD) patients who are being treated with immunosuppressive drugs, specifically biological therapies (such as vedolizumab and infliximab). We will follow IBD patients who will be attending infusion centres for routine infusion treatments. We will report on sero-prevalence (number of persons in a population who test positive for a disease based on serology (blood serum) specimens) over time, risk factors for infection and outcomes of COVID-19 exposure in these patients. We will also report on how these patients respond to vaccination, comparing vaccines currently available in their respective countries.


The study objectives are to:
(1) determine the seroprevalence and incidence over time of antibodies to SARS-CoV-2 in IBD patients receiving infusion medications,
(2) identify social, clinical, treatment-related, biologic factors that associate with seropositivity and asymptomatic disease, and
(3) characterize the systemic immune response to SARS-CoV-2 in these patients


Miami University, USA
All India Institute of Medical Sciences, India
Hôpital Saint-Louis, France
Icahn School of Medicine at Mount Sinai, USA
Örebro University Hospital, Sweden
Barts Health NHS Trust, UK
University of Oxford, UK
Chinese University of Hong Kong, Hong Kong
University of Chicago, USA
Mount Sinai Hospital, University of Toronto, Canada
Instituto Steinwurz de Saúde do Intestino, Brazil
University Hospitals Leuven, Belgium
Hyogo College of Medicine, Japan

Universidade Federal do Rio de Janeiro, Brazil

Post Graduate Institute of Medical Education & Research, India




Professor Jack Satsangi

Lee Placito Professor of Gastro-intestinal Disease at the University of Oxford

Dr Serre-Yu Wong

Instructor of Medicine (Gastroenterology) at the Icahn School of Medicine at Mount Sinai




Director of the Helmsley IBD Center at Mount Sinai


Professor Walter Reinisch

Medical University Vienna

Professor Séverine Vermeire

University Hospitals Leuven

Dr Flavio Steinwurz

Instituto Steinwurz de Saude do Intestino


Professor Matthieu Allez

Hôpital Saint-Louis

Dr Mark Silverberg

Mount Sinai Hospital, University of Toronto

Professor Vineet Ahuja

All India Institute of Medical Sciences

Professor Jonas Halfvarson

Örebro University Hospital

Professor James Lindsay

Barts Health NHS Trust

Dr Kenji Watanabe

Hyogo College of Medicine



Siew Chien Ng

Chinese University of Hong Kong

David Ruben

University of Chicago

Professor Maria Abreu

University of Miami



David Rubin

University of Chicago

Usha Dutta


Post Graduate Institute of Medical Education & Research

Dr Cyrla Zaltman

Universidade Federal do Rio de Janeiro

Dr Peter
Thelin Schmidt

Ersta Hospital,  Department of Medicine